Market Cap
$325.5M
CABA
Cabaletta Bio, Inc.
$1.86 ▼ -1.85%
Prev close $1.89Market cap$325.5M
ConsensusStrong Buy
12-mo target$13.25 (+614.3%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (7/10)31 New Institutional Positions9 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CABA right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (81%)
Inst. Holders
50 funds
Inst. Value
$315.0M
Inst. Activity
31 buys / 9 sells
Social Sentiment
71° Bullish
SEC Reports
16
Press Releases
1
Price chart 30d -48.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 21, 2026 short_volume
Sep 14, 2026 SEC Short Volume: CABA — 57.1% short (1.2M / 2.0M)
Short: 1,150,031 | Exempt: 21,956 | TRF Vol: 2,014,534 | Short Ratio: 57.1% | Off-exchange volume (d
Cabaletta Bio reports that warrants issued in a June 2025 public offering expired on September 12, 2026, and that 97% (4
8-K — Impact 4/10
A significant institutional cluster formed in Cabaletta Bio (CABA) during Q2 2026, with 15 buyers accumulating $66.0M in
INST-CLUSTER — Impact 5/10
Cabaletta Bio reported Q2 2026 EPS of -$0.34, beating consensus of -$0.37 by 8.1%, with no revenue. The company highligh
PRESS-RELEASE — Impact 4/10
Jun 30, 2026 Inst.
JENNISON ASSOCIATES LLC — DOUBLED
20,033,730 shares ($62.3M)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
10,754,701 shares ($33.4M)
Jun 9, 2026 Insider
Brun Scott C. was granted 22,000 shares
Director
Jun 9, 2026 Insider
Bollard Catherine was granted 22,000 shares
Director
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
81% rate it Buy or better · 16 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 1, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 14, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| May 15, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| May 4, 2026 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Aug 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Jul 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Jun 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| May 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Apr 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Mar 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Feb 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% |
Price targets
Where 8 covering analysts think CABA trades over the next 12 months.
$13.25 +614.3% upside Strong Buy
Current$1.86 Low$3.00 Median$13.50 High$30.00 8 analysts
$3.00$30.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood -16.7%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
71°
Bullish
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 5 bullish, 3 bearish, 0 mixed, 8 neutral · avg impact 5.1/10.Plus 1 press releases.
NEUTRAL8-K4/10
Cabaletta Bio reports that warrants issued in a June 2025 public offering expired on September 12, 2
Sep 14, 2026
BULLISHINST-CLUSTER5/10
A significant institutional cluster formed in Cabaletta Bio (CABA) during Q2 2026, with 15 buyers ac
Aug 15, 2026
NEUTRALPRESS-RELEASE4/10
Cabaletta Bio reported Q2 2026 EPS of -$0.34, beating consensus of -$0.37 by 8.1%, with no revenue.
Aug 13, 2026
NEUTRAL8-K4/10
Cabaletta Bio reported Q2 2026 net loss of $-0.34 per share, which is in line with the consensus est
Aug 13, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 21, 2026
short_volume
Short Volume: CABA — 57.1% short (1.2M / 2.0M)
Short: 1,150,031 | Exempt: 21,956 | TRF Vol: 2,014,534 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
Sep 18, 2026
short_volume
Short Volume: CABA — 72.2% short (1.2M / 1.7M)
Short: 1,205,655 | Exempt: 0 | TRF Vol: 1,669,366 | Short Ratio: 72.2% | Off-exchange volume (dark pool + OTC)
Sep 17, 2026
short_volume
Short Volume: CABA — 59.6% short (1.2M / 2.0M)
Short: 1,189,356 | Exempt: 7,025 | TRF Vol: 1,995,220 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
Sep 16, 2026
short_volume
Short Volume: CABA — 55.0% short (1.4M / 2.6M)
Short: 1,441,939 | Exempt: 131,920 | TRF Vol: 2,620,896 | Short Ratio: 55.0% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_volume
Short Volume: CABA — 62.2% short (2.2M / 3.5M)
Short: 2,172,609 | Exempt: 142,252 | TRF Vol: 3,491,650 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.31 | $-0.34–$-0.24 | 30.5% | +0.0% | 1↑ 2↓ | $0.0B | 5 |
| Next Q | $-0.31 | $-0.35–$-0.24 | 22.2% | +0.0% | 1↑ 2↓ | $0.0B | 5 |
| Current FY | $-1.36 | $-1.55–$-1.15 | 35.4% | +0.0% | 1↑ 2↓ | $0.0B | 5 |
| Next FY | $-1.19 | $-1.29–$-1.02 | 12.3% | +19.5% | 0↑ 2↓ | $0.0B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.306 | — |
| 7d ago | $-0.306 | — |
| 30d ago | $-0.306 | — |
| 60d ago | $-0.315 | +0.009 |
| 90d ago | $-0.315 | +0.009 |
Institutional ownership
Which big funds own CABA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $315.0M total value (101,306,847 shares) as of 2026-Q2. Top holders: JENNISON, BlackRock,, ADAGE. Net buying activity: 31 institutions added/increased vs 9 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| JENNISON ASSOCIATES LLC | 20,033,730 | $62.3M | 19.8% | DOUBLED +123.3% |
| BlackRock, Inc. | 10,754,701 | $33.4M | 10.6% | DOUBLED +353.2% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 9,174,758 | $28.5M | 9.1% | — |
| STATE STREET CORP | 7,839,305 | $24.4M | 7.7% | DOUBLED +1568.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,227,018 | $22.5M | 7.1% | ADD +79.4% |
| Woodline Partners LP | 4,200,142 | $13.1M | 4.1% | DOUBLED +235.9% |
| NORGES BANK | 4,112,401 | $12.8M | 4.1% | NEW |
| CITADEL ADVISORS LLC | 3,522,112 | $11.0M | 3.5% | NEW |
| GEODE CAPITAL MANAGEMENT, LLC | 3,459,464 | $10.8M | 3.4% | DOUBLED +205.3% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2,820,500 | $8.8M | 2.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| JENNISON ASSOCIATES LLC | DOUBLED | 8,970,578 | 20,033,730 | +123.3% | $62.3M |
| BlackRock, Inc. | DOUBLED | 2,373,003 | 10,754,701 | +353.2% | $33.4M |
| STATE STREET CORP | DOUBLED | 469,978 | 7,839,305 | +1568.0% | $24.4M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 4,028,991 | 7,227,018 | +79.4% | $22.5M |
| Woodline Partners LP | DOUBLED | 1,250,242 | 4,200,142 | +235.9% | $13.1M |
| NORGES BANK | NEW | — | 4,112,401 | — | $12.8M |
| CITADEL ADVISORS LLC | NEW | — | 3,522,112 | — | $11.0M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 1,133,245 | 3,459,464 | +205.3% | $10.8M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 783,220 | 2,211,825 | +182.4% | $6.9M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 5,903,281 | 2,068,491 | -65.0% | $6.4M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 11 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Brun Scott C. | Director | AWARD | 22,000 | — | — |
| Jun 9, 2026 | Bollard Catherine | Director | AWARD | 22,000 | — | — |
| Jun 9, 2026 | HENRIQUES RICHARD C JR | Director | AWARD | 22,000 | — | — |
| Jun 9, 2026 | Simon Mark | Director | AWARD | 22,000 | — | — |
| Jun 9, 2026 | Tomasello Shawn | Director | AWARD | 22,000 | — | — |
| Mar 2, 2026 | Gerard Michael | General Counsel | AWARD | 175,000 | — | — |
| Mar 2, 2026 | Binder Gwendolyn | President, Science & Tech. | AWARD | 225,000 | — | — |
| Mar 2, 2026 | Chang David J. | Chief Medical Officer | AWARD | 225,000 | — | — |
| Mar 2, 2026 | Das Arun | Chief Business Officer | AWARD | 175,000 | — | — |
| Mar 2, 2026 | Nichtberger Steven | President & CEO | AWARD | 674,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CABA.
Shares short
33,325,453
Settlement Sep 15, 2026
Change vs prior
-19.6%
Semi-monthly cycle
Days to cover
5.2
At avg daily volume
Of shares outstanding
≈19.7%
Estimate — not % of float
All CABA filing & press-release reports (17)
- 8-K reportSep 14, 2026
- INST-CLUSTER reportAug 15, 2026
- PRESS-RELEASE reportAug 13, 2026
- 8-K reportAug 13, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 5, 2026
- DEFA14A reportJun 1, 2026
- 8-K reportMay 14, 2026
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- 8-K reportMay 4, 2026
- 424B5 reportMay 4, 2026
- 8-K reportMay 4, 2026
- DEFA14A reportApr 28, 2026
- 8-K reportApr 20, 2026
- PRESS-RELEASE reportMar 23, 2026
- INST-CLUSTER reportFeb 28, 2026